Target intelligence / Profile preview

Calcium and Phosphorus (Ca/P)

Target
Ca/P
Molecular classification
Inorganic ion, Mineral, Electrolyte
01

Overview

Calcium and phosphorus are essential minerals that serve as the primary structural components of the skeletal system, primarily in the form of hydroxyapatite crystals. Calcium is a critical secondary messenger in intracellular signaling, facilitating muscle contraction, neurotransmitter release, and blood coagulation (StatPearls, 2023). Phosphorus is a vital component of nucleic acids, phospholipids, and high-energy phosphates like ATP, playing a central role in cellular energy metabolism (NIH, 2023). The homeostasis of these minerals is tightly regulated by a complex network involving parathyroid hormone (PTH), calcitriol (active vitamin D), and fibroblast growth factor 23 (FGF23) (KDIGO, 2017). Dysregulation of this balance, often seen in chronic kidney disease, leads to mineral and bone disorder (CKD-MBD), characterized by bone fragility and extraskeletal calcification (Nature Reviews Nephrology, 2020). While not a single molecular target, pharmacological management involves using phosphate binders to limit absorption or calcimimetics and vitamin D analogs to modulate the regulatory hormones (Journal of the American Society of Nephrology, 2016).

Other names
Calcium and PhosphateMineral metabolismCalcium-phosphate homeostasisCa-P productSerum mineralsCalcium-phosphorus axis
02

Mechanism of action

Therapeutic strategies focus on maintaining mineral homeostasis through the use of phosphate binders that sequester dietary phosphate in the gastrointestinal tract, and the use of vitamin D analogs or calcimimetics to regulate the hormonal axes (PTH/FGF23) that control systemic calcium and phosphorus levels (StatPearls, 2023; KDIGO, 2017).

03

Biological functions

Bone mineralizationSignal transductionEnergy metabolismStructural supportAcid-base balance
04

Disease associations

Chronic kidney disease-mineral and bone disorder (CKD-MBD)OsteoporosisHyperphosphatemiaHypocalcemiaVascular calcificationSecondary hyperparathyroidism
05

Safety considerations

Vascular calcificationHypercalcemiaGastrointestinal distressAdynamic bone disease
06

Interacting drugs

Calcium carbonate

7 more in the full profile.

07

Biomarkers

Serum calciumSerum phosphorusCalcium-phosphorus productIntact parathyroid hormone (iPTH)Fibroblast growth factor 23 (FGF23)

Beyond the preview

Go deeper on Calcium and Phosphorus (Ca/P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium and Phosphorus (Ca/P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call